Study #2016-0252
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-Naive Glioblastoma in the Adjuvant or Recurrent Setting
MD Anderson Study Status
Not Accepting
Treatment Agent
VAL-083, Dianhydrogalactitol
Description
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
Study phase:
Phase II
Physician name:
Barbara O'Brien
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-274-8956
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.